Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

739 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
Denton CP, Hachulla É, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL; Raynaud Study Investigators. Denton CP, et al. Among authors: frey a. Arthritis Rheumatol. 2017 Dec;69(12):2370-2379. doi: 10.1002/art.40242. Arthritis Rheumatol. 2017. PMID: 29193819 Free PMC article. Clinical Trial.
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Sitbon O, et al. Among authors: frey a. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. N Engl J Med. 2015. PMID: 26699168 Free article. Clinical Trial.
Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A; CONSCIOUS-1 Investigators. Macdonald RL, et al. Among authors: frey a. Stroke. 2008 Nov;39(11):3015-21. doi: 10.1161/STROKEAHA.108.519942. Epub 2008 Aug 7. Stroke. 2008. PMID: 18688013 Clinical Trial.
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
O'Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M; Randomized Intravenous TeZosentan Study-4 Investigators. O'Connor CM, et al. Among authors: frey a. J Am Coll Cardiol. 2003 May 7;41(9):1452-7. doi: 10.1016/s0735-1097(03)00194-3. J Am Coll Cardiol. 2003. PMID: 12742280 Free article. Clinical Trial.
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G. Kaluski E, et al. Among authors: frey a. J Am Coll Cardiol. 2003 Jan 15;41(2):204-10. doi: 10.1016/s0735-1097(02)02708-0. J Am Coll Cardiol. 2003. PMID: 12535809 Free article. Clinical Trial.
Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N. Macdonald RL, et al. Among authors: frey a. Lancet Neurol. 2011 Jul;10(7):618-25. doi: 10.1016/S1474-4422(11)70108-9. Epub 2011 Jun 2. Lancet Neurol. 2011. PMID: 21640651 Clinical Trial.
739 results